Integrin 2 1 (GP Ia/IIa) is a major platelet receptor for collagen, containing its collagen binding site within the 2 I domain. 2 1 changes conformation upon platelet activation, increasing its affinity for collagen. We observed that two antibodies known to bind within the 2 I domain, 12F1 and 6F1, bound preferentially to ADP-activated platelets. Interestingly, when whole blood was perfused over a surface coated with either 12F1 or 6F1, only 6F1 supported the adhesion of unstimulated platelets. To test whether the interaction of GP Ib with VWF directly activates 2 1, we used 12F1 as a probe of integrin activation. We perfused blood over a surface coated with a mixture of VWF A1 domain (a GP Ib ligand) and 12F1 or VWF A1 and mouse IgG. Platelets rolled and did not attach stably on the A1/IgG surface, but they firmly bound and covered the A1/12F1 surface. We corroborated that 12F1 binds an active conformation of the I domain by showing that it binds with higher affinity to a gain-of-function mutant than to either wild-type I domain or a lossof-function mutant. These results strongly suggest that the interaction of platelet GP Ib with VWF mediates the activation of 2 1, increasing its affinity for collagen.
Introduction
The integrin 2 1, also called glycoprotein (GP) Ia-IIa, is a major collagen receptor in platelets. 1, 2 This receptor plays a vital role in mediating the firm adhesion of platelets from flowing blood as they act to seal vascular defects. [3] [4] [5] When the integrity of the lining endothelium is disrupted, the circulating platelets make their first contact with the exposed subendothelium via the interaction of the GP Ib-IX-V complex on their surfaces with subendothelial von Willebrand factor (VWF) bound to collagen. This initial contact decelerates the platelets, allowing 2 1 to bind collagen. The interaction arrests the platelets and contributes to their activation and aggregation.
It appears that high-affinity binding of collagen by 2 1 requires the integrin to assume an active conformation. In platelets, 2 1 activation can be detected by an increase in the binding of soluble collagen to platelets stimulated with agonists such as ADP, thrombin, and the GP VIbinding collagen related peptide (CRP). 6 In fact, very recently Schoolmeester et al., 7 reported that the activated conformation of platelet 2 1 could be detected by an antibody against the 2-I domain.
Although it has been proposed that the GP Ib-IX-V complex and 2 1 play synergistic roles in platelet adhesion, 3 there is no direct evidence to demonstrate that the initial interaction of the GP Ib-IX-V complex with VWF activates 2 1.
Within the 2 subunit, the I domain (amino acids 140-349) contains the principal binding site for collagen. Like other I domains, the 2 I domain contains a cation-binding site within a motif known as the metal ion-dependent adhesion site (MIDAS), 8 which explains why collagen-induced platelet adhesion and activation require divalent cations. A recombinant 2 I domain has been reported that inhibits the interaction of platelets with collagen and extracellular matrix (ECM) under flow. 4 hypothesize that a conformational shift switches the I domain from a low affinity to a high affinity state as the result of the activation of 2 1.
Support for this hypothesis came also from results obtained with the anti-human 2 integrin monoclonal antibodies 12F1 and 6F1. 9 Both antibodies were capable of blocking the inhibitory effect of the isolated 2 I domain on collagen-induced platelet aggregation (CIPA) but themselves failed to inhibit CIPA in platelet-rich plasma (PRP). A likely explanation is that the epitopes recognized by the two antibodies are exposed in the isolated I domain while being masked in the intact 2 1 on platelets. A similar activation-dependent epitope has been described within IIb 3, which binds the antibody PAC-1 only when the platelets have been activated. 12 In this study, we demonstrate that 12F1 and 6F1 each has a higher affinity on activated platelets than on unstimulated platelets. We took advantage of this finding to demonstrate that the interaction of the GP Ib-IX-V complex with its binding site on VWF, the A1 domain, is sufficient to activate 2 1 and enable the firm adhesion of platelets in flowing blood to a mixed matrix of VWF A1 and 12F1. Finally, by mutagenesis of the 2 I domain, we demonstrate that 12F1 binds preferably to the high-affinity conformation of the domain.
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Materials and Methods
Reagents and Antibodies-We used three monoclonal antibodies in these studies, 12F1, 6F1, and P1E6, the first two recognizing the 2 I domain and P1E6 binding the 2 subunit. 12F1 was obtained from Pharmingen and from Dr. Virgil L. Woods (University of California, San Diego, CA), 6F1 from Dr. Barry Coller (The Rockefeller University, New York, NY), and P1E6 13 and mouse IgG were purchased from Calbiochem (San Diego, CA). Recombinant VWF A1 and wild-type and Y285F mutant 2 I domains were expressed in bacteria and purified as described earlier. 9, 10, 14 All of the recombinant I domains were monomeric, as previously determined by either SDS-PAGE or gelfiltration chromatography. 10, 14, 15 Construction, expression and purification of the Y285F/E318W mutant-The gain-offunction 2 I domain mutant, Y285F/E318W, was constructed by introducing the E318W mutation into the vector containing the Y285F mutation (pQE9-2-I/Y285F) using the QuikChange II XL site-directed mutagenesis kit (Stratagene, LA Jolla, CA). As per instructions supplied by the manufacturer, we introduced the mutation by polymerase chain reaction using two complementary oligonucleotide primers containing the mutation (5´ primer = GTGTCTGATTGGGCAGCTC and the 3´ primer = GAGCTGCCCAATCAGACAC). The mutant insert was sequenced to confirm the presence of the mutation. The recombinant Y285F/E318W mutant was expressed in E. coli as a fusion protein containing the 12 residue His tag (MRGSHHHHHHGS) at the N terminus and purified as described previously for the Y285F mutant.
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Surface Plasmon Resonance Collagen Binding Assay-Surface plasmon resonance binding studies were performed using a BIAcore 2000 system (BIAcore, Piscataway, NJ) as previously described, with minor modifications. [16] [17] [18] Either acid-soluble collagen type I from human placenta (250 µg/ml in 50 mM sodium acetate, pH 4.8) or bovine serum albumin (BSA, as control) was . To assess platelet adhesion, we perfused anticoagulated whole blood through the chamber for 2 min or the flow was stopped for 1
For personal use only. on . by guest www.bloodjournal.org From 8 min, then washed the coverslip with TBS and visualized the adherent platelets by phase-contrast microscopy. In other experiments, we studied the platelet interactions with these substrates using platelets labeled with the fluorescent dye mepacrine (quinacrine dihydrochloride; Sigma) at a final concentration of 200 µg/ml. These experiments were recorded in real time on videotapes and 10 images were captured from tapes to quantify the number of adherent platelets. In some experiments, whole blood was incubated with 10 U/ml apyrase (grade III, Sigma), 10 µg/ml aspirin, or 10 µM Preparation of plasma-free blood-Plasma-free blood was prepared as described elsewhere with some modifications. 20 Blood was collected from normal donors into plastic syringes containing one part of acid-citrate-dextrose (pH 4.5) (ACD). The blood was supplemented with 2 U/ml of the ADP scavenger apyrase (grade III or VII, Sigma), 10 µM of PGE 1 and 5 mM EDTA to block platelet activation, and was centrifuged at 2100 x g for 13 min at room temperature. The supernatant plasma was discarded and the cells were resuspended to their original volume with Hepes-Tyrode buffer (10 mM Hepes, 138 mM NaCl, 2.7 mM KCl, 0.4 mM NaH 2 PO 4 , 10 mM NaHCO 3 , and 5 mM dextrose), pH 6.5 containing 1 U/ml apyrase and 5 mM EDTA. The suspended cells were centrifuged again and the supernatant was removed. The process was repeated twice more with no apyrase in the third wash cycle. After the last centrifugation, the cells were resuspended in Hepes-Tyrode buffer pH 7.4 containing 20 mg/ml BSA.
Preparation of A1/collagen coated dishes -Acid-soluble human placental collagen type III in 50 mM acetic acid was diluted to 100 µg/ml in 65 mM sodium phosphate buffer, pH 6.5, and added to The dishes were then washed twice with phosphate buffered saline, pH 7.4 (PBS) and blocked with 3% BSA in TBS for one hour at 37 o C. After one washed the monomeric recombinant VWF-A1 (2 µM) was then added to the dishes and incubated for 30-45 min at 37 o C. The dishes were then used immediately in blood perfusion studies as described below.
Flow Assays-The flow assays were performed as described above and elsewhere. 10, 14 Briefly, the collagen-coated dish formed the lower surface of the parallel-chamber. Plasma-free blood was perfused through the chamber for 2 min, followed by TBS. For antibody inhibition studies, plasmafree blood was incubated with 15 µg/ml of either 6F1 or the function-blocking GPIb monoclonal antibody 6D1 for 15 min at room temperature before the attachment assay. Tethered platelets were observed with phase-contrast objectives and the images recorded by videomicroscopy. The number of platelets tethered to the surface was determined by overlaying a 15 square grid on 6 frames and counting and averaging the number of platelets in 6 randomly selected squares. For the control and the inhibitory experiments, the whole frame was counted. All experiments were performed in duplicate and on different days.
Protein Quantitation-Protein concentration was determined by the BCA method (Pierce Chemical Co., Rockford, IL). Coomassie Blue staining of SDS-PAGE gels was used to assess the purity of the recombinant proteins.
Results
Antibody 12F1 recognizes an active conformation of integrin 2 1-We evaluated whether an active conformation of integrin 2 1 can be detected through increased binding of monoclonal antibodies, much as the active form of IIb 3 is recognized by the antibody PAC-1.
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We initially evaluated two antibodies, 6F1 and 12F1, both known to bind within the I domain of the 2 subunit. 9 Both antibodies bound unactivated platelets above the background level set by an irrelevant antibody, and the binding of both increased with ADP activation of the platelets, 12F1 displaying the most marked increase (Figure 1 ). Increased binding did not result from increased surface expression of the integrin, as another 2 antibody, P1E6, did not display differential binding depending on the activation state of the platelets.
We then evaluated whether the two antibodies could detect the active conformation of the integrin under conditions of flow. For this, we perfused whole blood at a high shear rate (1500s
over a surface coated with either 6F1 or 12F1. Unactivated platelets rapidly adhered to the 6F1 surface (Figures 2A and 2B ) but, unexpectedly, not to the 12F1 surface. Identical results were obtained when flow was interrupted for one minute to allow the platelets to interact with the surface-bound antibody and then resumed ( Figure 2C ). This indicates that the binding of immobilized 12F1-resting 2 1 is not strong enough to support platelet firm adhesion under a higher shear stress. Nevertheless, the immobilized 12F1 is capable of recognizing the active conformation of 2 1. When ADP-treated blood (in the presence of the IIb 3 blocker, 10E5, to prevent platelet aggregation) was incubated with the 12F1-coated surface for 1 min before flow was initiated, the number of firmly adherent platelets was 9 times greater than in untreated blood (data not shown). However, the 2 1-12F1 bond was unable to capture the platelets from the flowing blood because without the brief incubation period only a very small number of ADP-activated platelets adhered to the 12F1 surface (data not shown).
We took advantage of the observation that 2 1-mediated attachment to a 12F1 surface requires both platelet tethering and integrin activation to evaluate whether the first molecular interaction in the sequence of platelet adhesion from flowing blood-the binding of the GP Ib-IXFor personal use only. on August 30, 2017. by guest www.bloodjournal.org From V complex to VWF-is able to directly signal to activate 2 1 and enable firm adhesion to collagen.
12F1 is able to act as a surrogate for the 2 1-binding site of collagen, obviating the need to use collagen, which has several receptors on the platelet surface, 21 and is difficult to obtain in pure form.
We therefore perfused whole blood over a surface coated with a mixture of the isolated VWF A1 domain-containing the binding site for GP Ib-and 12F1, reasoning that if the binding of the platelets to A1 activated 2 1, they would become firmly adherent to the surface. Surfaces coated with mixtures of A1 and 6F1 or A1 and mouse IgG served as positive and negative controls, respectively. We observed extensive platelet deposition on coverslips coated with either A1/12F1 or A1/6F1, and virtually no adherent platelets on the surface coated with A1/mouse IgG ( Figure 3 ).
When analyzed in real time, the platelets perfused over the A1/12F1 surface were seen to arrest on the surface very soon after they first attached, whereas those on the A1/mouse IgG surface rolled continuously across the surface and failed to attach firmly. 
12F1 binding is favored by the open conformation of the 2 I domain-Enhanced
binding of 12F1 within the 2 I domain would be seen if platelet activation either unmasks the epitope or induces a high-affinity conformation of the I domain. To distinguish between the two, we compared the binding of the antibody to the wild-type, recombinant I domain with its binding to two mutants, one with lower affinity for collagen, one with higher affinity. As described earlier, the Y285F mutant 2 I domain binds collagen with lower affinity than does the wild-type 2 I domain. 10 In fact, based on the comparison of the crystal structure of the I domain alone with that of the I domain in complex with a collagen peptide, we proposed that the Y285F mutant adopts a closed low-affinity conformation ( Figure 5A ). 10 To construct an I domain with a high-affinity conformation, we introduced a second mutation into the Y285F mutant, E318W ( Figure 5A ). Aquilina et al. 22 showed that this mutation, by itself, resulted in a gain of collagen-binding function.
In our hands, the double mutant, Y285F/E318W, also displayed gain-of-function, binding collagen with higher affinity than either Y285F or wild-type 2 I domain, as demonstrated using surface plasmon resonance ( Figure 5B) . Similarly, the affinity of the double mutant for 12F1 was greater than the affinity of the Y285F mutant and slightly greater than the affinity of the wild-type 2 I domain ( Figure 6 ), proving that the Y285F mutation altered antibody binding allosterically.
Discussion
Platelet adhesion to sites of vessel injury, particularly in regions of rapidly flowing blood, has been modeled as involving sequential adhesive interactions that initially attach the platelets from bulk flow, allow them to decelerate by rolling, and then allow them to firmly attach to the exposed collagen. Firm attachment involves integrins, most prominently 2 1, which generally must be activated to bind their ligands with high affinity. Recent studies have demonstrated that 2 1, like other integrins, can indeed assume an active conformation capable of binding collagen with high affinity. 6, 23, 24 This active conformation is induced when platelets are stimulated by a number of soluble agonists, including ADP, thrombin and the GP VI-binding peptide, CRP. Of these, only CRP activates a receptor that would be able to activate the integrin early in the adhesive cascade. In fact, it has been proposed that collagen engagement of GP VI during the adhesive process is a prerequisite to integrin activation and firm platelet adhesion. 6, 23, 25 However, the potential for signals from the GP Ib-IX-V complex to activate 2 1 has never been addressed directly, largely for technical reasons, among them being the fact that both VWF and collagen have more than one receptor on the platelet surface. For this reason, we investigated whether a monoclonal antibody could be used as a surrogate for collagen to recognize the active state of the integrin, much as has been described for the IIb 3 antibody PAC-1, which recognizes only the active, ligand-competent form of IIb 3.
12
Two antibodies tested, 12F1 and 6F1 in solution, bound activated platelets at higher levels than they bound unstimulated platelets. When immobilized on the surface, only one of these antibodies, 6F1, was able to support the adhesion of unstimulated platelets under flow.
Immobilized 12F1 only supports the adhesion of activated platelets under static conditions. 
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However, once activated platelets bound immobilized 12F1, they remained firmly adhered, even at elevated shear stresses.
Further evidence that 12F1 recognizes an active form of 2 1 comes from studies with the isolated I domains. The antibody bound best to a gain-of-function form of the I domain with a structure predicted to be the one assumed when the domain binds collagen, 11 and least well to a form with low collagen-binding activity ( Figure 5A ). These data are in agreement with those of Jung et al., 6 who reported that 2 1 on agonist-stimulated platelets bound significantly more soluble collagen than did the integrin on resting platelets. These investigators also noted that the affinity for collagen was different between platelets activated with thrombin and those activated with ADP.
Thus, 2 1 on platelets can assume at least two different conformational states of activation, and possibly more. In the intact integrin, the antibody 12F1 recognizes an active conformation.
This property of the 12F1 made it possible for us to design a system to test GP Ib-mediated activation of 2 1 using ligands relatively restricted in their reactivity with the two receptors: the A1 domain of VWF, containing the GP Ib-IX-V binding site, and 12F1, a specific probe of 2 1 activation. The ability of a surface coated with a mixture of these two proteins to support the rapid and firm adhesion of platelets under flow argues strongly that signals emanating from GP Ib after it binds A1 activate the integrin to a high-affinity conformation that can bind 12F1. These signals are transmitted rapidly, as we observed the platelets to arrest immediately after their initial contact with the matrix.
These signals are not only rapid, they may also be local or specifically induce only a small number of changes normally associated with platelet activation. For example, our failure to observe the formation of microthrombi on the A1/12F1-coated surface suggests that the signals were insufficient to activate receptors on the side of the platelet not in contact with the matrix. That the signals may act locally is made more likely by the known proximity of the GP Ib-IX-V complex and 2 1 on the platelet membrane. 2, 15, 26 This proximity should allow the approximately 20:1 ratio of GP Ib to 2 1 complexes to concentrate the signals at the integrin. A second possibility is suggested by the fact that both receptors are attached through their cytoplasmic domains to the cytoskeletal protein filamin A. [27] [28] [29] Thus, it is possible that a direct mechanical signal is transmitted to activate 2 1 when torque is applied to ligand-engaged GP Ib complex. This possibility is particularly attractive when one considers that the GP Ib-VWF bond is subjected to considerable torque as the platelet attaches from flowing blood to the immobile vessel wall. 30, 31 Such stress would be directly transferred to cytoskeletal structures attached to the platelet receptor.
Another implication of this work is that firm adhesion of platelets at sites of vessel injury does not require GP VI-generated activation signals. However, such signals may be important for platelets to build thrombi, a possibility that we are currently examining.
In summary, we demonstrate that integrin 2 1 in platelets can be directly activated by the interaction of GP Ib with VWF. This activation is reflected in a conformational change of the I domain in the 2 subunit recognized by specific antibodies. Activation of 2 1 allows the integrin to mediate firm platelet attachment to collagen, which is then followed by platelet activation and aggregation. 
